Obexelimab for IgG4-related disease
The FDA is expected to decide on Obexelimab for IgG4-related disease by May 27, 2027, under a BLA from Zenas BioPharma.
What is being decided
Zenas BioPharma has a BLA under FDA review for Obexelimab in IgG4-related disease. Self-injected antibody that dials down B cells without depleting them. In the Phase 3 INDIGO trial it cut the risk of IgG4-RD flare by 56% over 52 weeks, with 73% of treated patients flare-free versus 45% on placebo, and reduced steroid use. Zenas disclosed the acceptance and date in its August 13, 2026 quarterly update.
Who this decision matters to
IgG4-related disease is a chronic fibroinflammatory condition characterized by tumor-like swelling in affected organs, dense lymphoplasmacytic infiltration rich in IgG4-positive plasma cells, storiform fibrosis, and often (but not always) elevated serum IgG4 levels. It can affect virtually any organ but most commonly involves the pancreas, bile ducts, salivary glands, lacrimal glands, kidneys, and retroperitoneum. Left untreated, it causes progressive organ damage and fibrosis.
Prevalence: Approximately 5 in 100,000 people; an estimated 57,000 diagnosed individuals in the U.S. as of 2024. See our full IgG4-Related Disease page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where IgG4-Related Disease treatment stands today
The approval of inebilizumab (Uplizna) in April 2025 was a turning point for IgG4-RD, but research is far from over. Trials are studying optimal duration of B-cell depletion therapy, whether early aggressive treatment prevents irreversible fibrosis, and how to manage the subset of patients who relapse despite B-cell targeted therapy. Ask your rheumatologist or treating specialist whether tissue biopsy has confirmed your diagnosis (serum IgG4 alone is insufficient), whether your current organ involvement warrants immediate inebilizumab or whether glucocorticoid induction is appropriate first, and whether PET-CT surveillance should be part of your monitoring plan to detect subclinical organ involvement. If you were initially misdiagnosed with cancer, lymphoma, or another autoimmune condition, re-evaluation by an IgG4-RD specialist at an academic center is worthwhile. Mass General, Mayo Clinic, and Stanford have dedicated IgG4-RD programs.
Meanwhile, 33 IgG4-Related Disease trials are recruiting
Whatever the FDA decides here, research on IgG4-Related Disease does not stop. A few currently enrolling studies, US sites first:
Other drugs Trial Friend tracks for IgG4-Related Disease
Get notified when new igg4-related-disease trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on Obexelimab?
The FDA's target decision date (PDUFA date) for Obexelimab in IgG4-related disease is May 27, 2027, disclosed by Zenas BioPharma. The agency can act before this date and occasionally runs past it.
What is Obexelimab being reviewed for?
Zenas BioPharma submitted a BLA for Obexelimab in IgG4-related disease. Self-injected antibody that dials down B cells without depleting them. In the Phase 3 INDIGO trial it cut the risk of IgG4-RD flare by 56% over 52 weeks, with 73% of treated patients flare-free versus 45% on placebo, and reduced steroid use. Zenas disclosed the acceptance and date in its August 13, 2026 quarterly update.
What happens after the Obexelimab decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Zenas press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.